All In Biotech

Drug Trial Radar · NCT00544960

A Randomized Phase 2 Study of AT-101 in Combination With Docetaxel in Relapsed/Refractory Non-Small Cell Lung Cancer

A Phase 2, Randomized, 2-Arm, Double-Blind Study of AT-101 in Combination With Docetaxel Versus Docetaxel Plus Placebo in Patients With Relapsed or Refractory Non-Small Cell Lung Cancer (NSCLC)

Last checked: Nov 19, 2026Latest source record: Aug 27, 2010 (this record)Source: ClinicalTrials.govMethods & limitations

Completed

Status

Completed

Enrollment

106

Actual

Start

Sep 2007

Primary completion

Nov 2008

Study completion Apr 2009

Sponsor

Lead sponsor
Ascenta TherapeuticsIndustry
Sponsor type
Industry
First posted
Oct 16, 2007

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 2
Allocation
Non randomized
Model
Crossover
Masking
Quadruple (participant, care provider, investigator, outcomes assessor)
Primary purpose
Treatment
Who can join
All sexes, from 18 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

This is a double- blind, multicenter, randomized Phase II study to evaluate the efficacy and safety of AT-101 in combination with docetaxel in relapsed/refractory non-small cell lung cancer

Conditions

  • Non-small Cell Lung Cancer

Interventions

  • AT-101 and docetaxelDrug

    AT-101 30 mg bid on days 1, 2, and 3 of each 21 day cycle, docetaxel, 75 mg/m2 on day 1 of each 21 day cycle; until progression or unacceptable toxicity develops

  • placebo and docetaxelDrug

    placebo 3 tabs bid on days 1, 2, and 3 of each 21 day cycle, docetaxel, 75 mg/m2 on day 1 of each 21 day cycle; until progression or unacceptable toxicity develops

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. duration of disease remissionTime frame: 12 months

Locations

18 sites in 3 countries. Site status is shown where the registry gives one.

  • Research Site

    Durham, North Carolina

  • Research Site

    Arkhangelsk, Russia

  • Research Site

    Chelyabinsk, Russia

  • Research Site

    Kaliningrad, Russia

  • Research Site

    Kazan', Russia

  • Research Site

    Moscow, Russia

  • Research Sites (4)

    Saint Petersburg, Russia

  • Research Site

    Samara, Russia

  • Research Site

    Stavropol, Russia

  • Research Site

    Voronezh, Russia

  • Research Site

    Yekaterinburg, Russia

  • Research Site

    Dnipropetrovsk, Ukraine

  • Research Site

    Donetsk, Ukraine

  • Research Site

    Kharkiv, Ukraine

  • Research Site

    Kyiv, Ukraine

  • Research Site

    Luhansk, Ukraine

  • Research Site

    Uzhhorod, Ukraine

  • Research Site

    Zaporizhzhya, Ukraine

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.